Repligen Co. (NASDAQ:RGEN) Stock Holdings Lowered by Corebridge Financial Inc.

Corebridge Financial Inc. cut its position in Repligen Co. (NASDAQ:RGEN) by 4.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 59,054 shares of the biotechnology company’s stock after selling 2,660 shares during the quarter. Corebridge Financial Inc. owned about 0.11% of Repligen worth $8,500,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of RGEN. UMB Bank n.a. raised its holdings in shares of Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 110 shares during the last quarter. Oppenheimer & Co. Inc. bought a new stake in Repligen during the 4th quarter valued at $216,000. Worldquant Millennium Advisors LLC raised its stake in Repligen by 11.9% during the 3rd quarter. Worldquant Millennium Advisors LLC now owns 50,276 shares of the biotechnology company’s stock valued at $7,482,000 after acquiring an additional 5,337 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Repligen by 1.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 363,379 shares of the biotechnology company’s stock worth $54,078,000 after acquiring an additional 5,478 shares during the period. Finally, Van ECK Associates Corp grew its stake in shares of Repligen by 7.8% in the fourth quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company’s stock worth $6,078,000 after purchasing an additional 3,066 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Repligen news, Director Margaret Pax bought 250 shares of the stock in a transaction on Monday, March 17th. The shares were bought at an average price of $150.69 per share, with a total value of $37,672.50. Following the purchase, the director now directly owns 1,043 shares in the company, valued at $157,169.67. The trade was a 31.53 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on RGEN shares. StockNews.com downgraded shares of Repligen from a “hold” rating to a “sell” rating in a report on Friday, February 21st. Royal Bank of Canada upped their price target on shares of Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research note on Friday, February 21st. JPMorgan Chase & Co. raised their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. HC Wainwright restated a “buy” rating and issued a $180.00 target price on shares of Repligen in a research report on Friday, February 21st. Finally, Evercore ISI started coverage on Repligen in a research report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 price target on the stock. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $178.64.

Repligen Trading Down 1.7 %

Shares of NASDAQ RGEN opened at $137.12 on Friday. The business has a fifty day simple moving average of $154.75 and a 200-day simple moving average of $148.22. The company has a market cap of $7.70 billion, a price-to-earnings ratio of -268.86, a P/E/G ratio of 4.54 and a beta of 0.95. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $187.25. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. Sell-side analysts predict that Repligen Co. will post 1.72 EPS for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.